Skip to main content
. Author manuscript; available in PMC: 2007 Jun 1.
Published in final edited form as: Hepatology. 2006 Jun;43(6):1202–1210. doi: 10.1002/hep.21183

Figure 4.

Figure 4

Effect of a JNK inhibitor on IL-1β suppression of human CYP7A1 reporter activity and HNF4α protein expression in human primary hepatocytes. A. Human CYP7A1 promoter/luciferase construct ph-298/luc (1μg) was transfected into HepG2 cells. Cells were pretreated with a JNK-specific inhibitor SP600125 (50 μM) for 1 hr before IL-1β (5 ng/ml) was added and cells were incubated for the time indicated. The error bars represent the standard deviation from the mean of triplicate assays of an individual experiment. N=3. *, Statistically significant (P<0.05): JNK inhibitor treatment vs. vehicle at 20h; #, Statistically significant (P<0.05): treatment vs. control of 0 h. B. Same human primary hepatocytes as in Fig. 2B were also pretreated with 50 μM SP600125 for 1 hr before being incubated with IL-1β (5 ng/ml) or CDCA (25μM) for the time indicated. Immunoblotting analysis was performed as in Fig. 2 in parallel.